Fei Yang1, Danhua Shen1, Junping Shi2. 1. Department of Pathology, Peking University People Hospital Beijing, China. 2. Department of Medical, OrigiMed Shanghai, China.
Abstract
BACKGROUND: NUT carcinoma is a rare aggressive squamous cell carcinoma subtype genetically characterized by NUTM1 rearrangements. NUT carcinoma can be easily misdiagnosed as an undifferentiated carcinoma or Ewing sarcoma due to its primitive differentiation. CASE PRESENTATION: We report a case of renal-derived NUT carcinoma diagnosed as a malignant small round-cell tumor resembling Ewing sarcoma/primitive neuroectodermal tumor where the diagnosis was revised to NUT carcinoma with a characteristic NUTM1 rearrangement based on next-generation sequencing (NGS). The patient received a standard NUT carcinoma treatment after recurrence but died of first-line chemotherapy failure due to advanced neoplasm progression. CONCLUSION: Routine NUT immunohistochemistry staining, NGS, and/or fluorescent in situ hybridization for poorly differentiated carcinoma and sarcoma can help avoid misdiagnosis of NUT carcinoma-related tumors, allowing patients to benefit from bromodomain and extra-terminal motif inhibitor therapy. IJCEP
BACKGROUND:NUT carcinoma is a rare aggressive squamous cell carcinoma subtype genetically characterized by NUTM1 rearrangements. NUT carcinoma can be easily misdiagnosed as an undifferentiated carcinoma or Ewing sarcoma due to its primitive differentiation. CASE PRESENTATION: We report a case of renal-derived NUT carcinoma diagnosed as a malignant small round-cell tumor resembling Ewing sarcoma/primitive neuroectodermal tumor where the diagnosis was revised to NUT carcinoma with a characteristic NUTM1 rearrangement based on next-generation sequencing (NGS). The patient received a standard NUT carcinoma treatment after recurrence but died of first-line chemotherapy failure due to advanced neoplasm progression. CONCLUSION: Routine NUT immunohistochemistry staining, NGS, and/or fluorescent in situ hybridization for poorly differentiated carcinoma and sarcoma can help avoid misdiagnosis of NUT carcinoma-related tumors, allowing patients to benefit from bromodomain and extra-terminal motif inhibitor therapy. IJCEP
Authors: Inga-Marie Schaefer; Paola Dal Cin; Latrice M Landry; Christopher D M Fletcher; Glenn J Hanna; Christopher A French Journal: Genes Chromosomes Cancer Date: 2018-08-14 Impact factor: 5.006
Authors: Michael A den Bakker; Berna H Beverloo; Marry M van den Heuvel-Eibrink; Cees A Meeuwis; Liane M Tan; Laura A Johnson; Christopher A French; Geert J L H van Leenders Journal: Am J Surg Pathol Date: 2009-08 Impact factor: 6.394
Authors: Daniel E Bauer; Chelsey M Mitchell; Kelly M Strait; Christopher S Lathan; Edward B Stelow; Sonja C Lüer; Somala Muhammed; Andrew G Evans; Lynette M Sholl; Juan Rosai; Eugenia Giraldi; Richard P Oakley; Carlos Rodriguez-Galindo; Wendy B London; Stephen E Sallan; James E Bradner; Christopher A French Journal: Clin Cancer Res Date: 2012-08-15 Impact factor: 12.531
Authors: Brendan C Dickson; Yun-Shao Sung; Marc K Rosenblum; Victor E Reuter; Mohammed Harb; Jay S Wunder; David Swanson; Cristina R Antonescu Journal: Am J Surg Pathol Date: 2018-05 Impact factor: 6.394
Authors: Todd M Stevens; Diana Morlote; Joanne Xiu; Jeffrey Swensen; Margaret Brandwein-Weber; Markku M Miettinen; Zoran Gatalica; Julia A Bridge Journal: Mod Pathol Date: 2019-02-05 Impact factor: 7.842
Authors: Bin Xu; Jie-Fu Chen; Judy Sarungbam; Satish Tickoo; Brendan C Dickson; Victor E Reuter; Cristina R Antonescu Journal: Genes Chromosomes Cancer Date: 2022-04-27 Impact factor: 4.263